FolioLanternBeta
HALOHalozyme Therapeutics, Inc.

Matthew Posard

Director at Halozyme Therapeutics, Inc., as of Oct 2, 2026Sold $2.6M of stock in the past 12 months: 100% under a disclosed plan.

Updated Oct 16, 2026 from SEC filings · covers Oct 17, 2025 to Oct 16, 2026
24K
shares sold, past 12 months
2
days with sales
$2.0M
largest single day, Sep 16, 2026
2
companies filed for

Share of stake sold and shares held at Halozyme Therapeutics, Inc. are being verified and not shown yet. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMarAprMayJunJulAugSep 2026: $2.0M under a disclosed plan$2.0MSepOct 2026: $568K under a disclosed planOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Halozyme Therapeutics, Inc. (HALO)DirectorMar 28, 2013Oct 2, 2026
Illumina, Inc. (ILMN)Former Sr VP & General ManagerMar 7, 2012May 30, 2013

Recent filings

The last 3 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.